Labiana Health, S.A. (BME:LAB)

Spain · Delayed Price · Currency is EUR

5.70

-0.05 (-0.87%)

At close: Oct 6, 2026

Market Cap	47.30M +56.2%
Revenue (ttm)	76.44M +13.5%
Net Income	2.57M +913.7%
EPS	0.37
Shares Out	8.30M
PE Ratio	15.60
Forward PE	7.32
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,905
Open	5.80
Previous Close	5.75
Day's Range	5.60 - 5.85
52-Week Range	4.00 - 8.20
Beta	0.63
Analysts	n/a
Price Target	n/a
Earnings Date	Apr 21, 2026

About Labiana Health

Labiana Health, S.A. develops, manufactures, sells, and markets animal and human health medicine products in Spain, rest of European Union, North America, and internationally. It offers anesthetics-sedatives, anti-infectives, anti-inflammatories, antiparasitics, hormonals, nutritional products, metabolism regulators, and vitamin products. The company also provides sterile and lyophilized dosage forms, and bacterial vaccines; and Fosfomycin trometamol under the Fosfomicina Labiana brand name. In addition, it offers contract development and manuf... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1958

Employees 373

Stock Exchange Madrid Stock Exchange

Ticker Symbol LAB

Full Company Profile

Financial Performance

In 2025, Labiana Health's revenue was 76.44 million, an increase of 13.46% compared to the previous year's 67.37 million. Earnings were 2.57 million, an increase of 913.67%.

Financial Statements